Skip to content 
Recently, there have been exciting news about innovation from enterprises in Jiangbei New District. Chongshi Biotechnology has successfully developed a malaria mRNA vaccine and its application has been approved for the National Science and Technology Major Project. Ruixi Medicine’s new drug has entered the third phase of clinical trials. Shengde Medical’s core medical system has been approved for market launch. Jique Intelligent Manufacturing has introduced an automatic welding robot without teaching. All these demonstrate the strong innovation vitality of the new district. Let’s take a look at these enterprises’ remarkable breakthroughs!
01 Develop mRNA vaccine for malaria! Chengshi Biotechnology has been approved for the national science and technology major project.
Recently, the “Development of Multivalent Malaria Vaccine” project under the national science and technology major project “Prevention and Control of Emerging and Pandemic Infectious Diseases” was officially approved for funding. Jiangbei New District Chengshi Biotechnology, as the core participating enterprise of the project, undertakes the research task of the sub-project “Malaria mRNA Vaccine with Multiple Periods and Multiple Targets”.
This project is led by the Shanghai Institute of Pharmaceutical Science of the Chinese Academy of Sciences. Chenshi Biotechnology, leveraging its advanced domestic mRNA underlying technology research capabilities, has been honoredly selected to join the “Industry-University-Research-Health-Testing” collaborative innovation cluster of this national major project.
Episode 2: The Intelligent Manipulator with Intrinsic Intelligence and No Teaching Required Makes a Grand Debut and Embarks on a New Journey in Welding!
Recently, Jichu Intelligent Manufacturing held a grand new product launch event under the theme of “Collecting talents, creating a brilliant future; Embodied intelligence, building an extraordinary future”. They showcased their brand-new CW5 welding robot and two core technological breakthroughs, presenting a disruptive solution for the welding industry and redefining the new height of intelligent manufacturing with their technological prowess! The CW5 welding robot launched this time features a golden parameter of 5kg load capacity and 1400mm arm extension, precisely adapting to small-load welding scenarios, balancing flexibility and operational range. Whether it’s precise small-piece welding or complex workpiece processing, it can handle them with ease. What’s more noteworthy is that CW5 is equipped with an autonomous teaching system independently developed by Jichu Intelligent Manufacturing, giving the robot the full-chain intelligent capabilities of perception – decision-making – execution. This completely breaks through the traditional welding technical bottlenecks and achieves a leap from automation to intelligence. At the same time, two industry-leading technological breakthroughs were also released： Welding Autonomous Teaching Technology： Completely eliminating the traditional cumbersome teaching process， through AI visual perception and intelligent path planning， the robot can autonomously identify the workpiece and generate welding trajectories， significantly reducing the operational threshold and improving production efficiency. Laser Weld Seam Tracking Technology: Real-time and precise tracking of the weld seam position， automatic compensation for workpiece errors， ensuring welding accuracy and stability， perfectly adapting to high-precision welding requirements in complex working conditions.
03 The only one in the world! Administration of its new drug for endometriosis in the uterine cavity in the domestic phase III clinical trial
On March 25th, Hope Medicine Inc. (and its partner Rui Medicine), a science-driven clinical-stage innovative biopharmaceutical company based in Jiangbei New District, announced that the phase III clinical trial of its globally-protected first-in-class monoclonal antibody drug HMI-115 for the treatment of endometriosis has completed the first patient administration at the lead institution in China, Beijing Union Hospital. It is worth noting that HMI-115 is currently the only non-hormonal treatment to have entered phase III clinical trials globally.
The current phase III clinical trial that has been initiated is a multi-center, randomized, double-blind, placebo-controlled study, aiming to verify the safety and efficacy of HMI-115 in treating moderate to severe pain associated with endometriosis. The treatment period is 24 weeks.
04 SD Medical’s Xcor™ Transcatheter Aortic Valve Replacement System Has Been Approved
Recently, Nanjing Shengde Medical Technology Co., Ltd. announced that its independently developed Xcor™ transcatheter aortic valve replacement system has been officially approved for market launch by the National Medical Products Administration (NMPA). This marks that in the field of interventional treatment of transcatheter aortic valves, clinicians and patients have yet another powerful domestic innovation option.
Based on the recent clinical studies published by multiple authoritative centers (such as West China Hospital, Xijing Hospital, Guangdong Provincial People’s Hospital, etc.), Xcor™ has demonstrated outstanding clinical advantages: Overcoming the complication bottleneck: In TAVR surgeries, new-onset conduction block and permanent pacemaker implantation (PPI) are important factors affecting the long-term prognosis of patients. Thanks to the precise positioning system and optimized stent structure, the impact of the Xcor™ valve on the surrounding conduction bundles during release has been effectively controlled. Multiple clinical studies and long-term follow-up results show that the rate of postoperative pacemaker implantation caused by the valve itself remains at 0 over a 3-year follow-up period. Significant hemodynamic improvement: Multicenter data indicate that the transvalvular pressure difference of patients after surgery has significantly decreased, the effective valve orifice area has significantly increased, and the patient’s cardiac function classification (NYHA) and quality of life scores have all been significantly and persistently improved. Wide anatomical applicability: For difficult high calcification lesions, bicuspid aortic valve (BAV), and patients with difficult vascular access, Xcor™ also shows extremely high surgical success rate and device success rate, demonstrating its outstanding ability to handle complex anatomical structures.
